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HAART-related nephropathies in HIV-infected patients. There
is no doubt that highly active antiretroviral therapy (HAART)
has been the most important progress in the therapy of hu-
man immunodeficiency virus (HIV)-infected patients in the last
decade. A growing number of observations suggest that the ben-
eficial effects of HAART also include improvement of HIV-
related renal complications. Consequently, the cohort of HIV-
infected patients requiring HAART has increased and includes
patients with preexisting nephropathies, whether related or un-
related to HIV infection. However, some antiretroviral drugs
may have renal- and life-threatening side-effects, especially if
underlying renal abnormalities exist. In this review, we focus
on those aspects that require particular attention in preventing
new health complications in HIV-infected patients.
Current guidelines for treatment of human immun-
odeficiency virus (HIV) infection recommend the com-
bination of three antiretroviral agents, two reverse
transcriptase inhibitors (RTI) plus one protease inhibitor,
or the association of three RTIs [1, 2]. These regimens of
highly active antiretroviral therapy (HAART) have dra-
matically reduced the morbidity and mortality of HIV
infection.
Nephropathies in HIV-1–infected patients have been
recognized for two decades [3, 4]. They consist mostly of
glomerular nephropathies, but also of vascular or tubu-
lointerstitial nephropathies [5]. Recently, a growing vol-
ume of virologic and histologic evidence suggests that
HIV-associated nephropathy (HIVAN), the most usual
form of HIV-1–related nephropathy, may be the conse-
quence of HIV-1 replication in the kidney. The possible
relation of HIVAN with HIV-1 replication in the kidney
correlates with epidemiologic and clinical data showing
that HAART may improve HIVAN.
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However, from a nephrologist’s point of view, one con-
sequence of this success has been the emergence of new
kidney diseases related to (1) a better control of the
HIV infection and (2) the potential nephrotoxicity of an-
tiretroviral therapies. Here we summarize the reported
renal adverse effects of the antiretroviral drugs and give
some insights into their pathophysiology. We try as well
to delineate a new characterization of kidney diseases
in HIV-1–infected patients since the beginning of the
HAART era. This new profile has been linked to better
control of HIV infection and to the potential nephrotox-
icity of some antiretroviral treatments.
HIVAN
The most common HIV-1–related nephropathy is
HIVAN, a focal segmental glomerulosclerosis (FSGS)
associated with severe cystic tubular lesions, leading to
chronic renal failure, especially in its collapsing variant
[6]. HIVAN usually affects black patients, and is known
to be a leading cause of end-stage renal disease (ESRD)
in this population in North America and in Europe [7–
11]. During the last 5 years, significant advances in the
pathophysiology of HIVAN have been achieved. Data
from animal models and from human renal biopsies tend
to point to HIV-1 infection of renal tubular cells and
podocytes as being responsible for the lesions observed
in HIVAN (for review, see [11]). Moreover, the recent
demonstration that renal tubular cells in patients with
HIVAN constitute a viral reservoir where active replica-
tion of HIV-1 is independent of that in peripheral blood
mononuclear cells strengthens the hypothesis of a direct
role of HIV-1 in HIVAN pathogenesis [12]. The HIV-1–
encoded protein Nef seems to be an important candidate
for HIV-1 nephrotoxicity since Nef is capable of inducing
podocyte abnormalities in vitro similar to those observed
in HIVAN [13]. Nonetheless, the efficacy of antiretrovi-
ral therapy on the course of HIVAN (see below) does
not constitute a solid argument for a direct role of HIV-1
in HIVAN as it might well also be related to its indirect
effect on systemic HIV-1 replication. In addition, it is not
clear if the renal reservoir of HIV-1 thought to be impli-
cated in HIVAN is affected by HAART or not [12].
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THE BENEFITS OF HAART
In the pre-HAART era, HIVAN was considered to
have a poor prognosis. In addition to the antiretroviral
therapy, two types of treatment were proposed to im-
prove the course of HIVAN: prednisone and angiotensin-
converting enzyme (ACE) inhibitors. Only one limited
prospective study [14] and several retrospective studies
[15–18] argue for the use of both corticosteroids and ACE
inhibitors in HIVAN. In most studies, however, therapeu-
tic results of ACE inhibitors and prednisone were poor,
especially when considering the infectious side-effects
of the latter. Antiretroviral therapy such as zidovudine
was considered of interest in delaying but not in prevent-
ing ESRD [19–21]. Nonetheless, in the pre-HAART era
these reports supported the idea that anti-HIV therapies
could be relevant in the therapeutic strategy of HIV-1–
related nephropathies [17, 19–21].
Since the onset of HAART, national epidemiologic
data show the reduction of incidence of ESRD due to
HIV-associated renal disease in the United States [5,
22]. This suggests that antiretroviral therapy may prevent
HIVAN or at least slow its course. Preliminary retrospec-
tive series or case reports support the efficacy of HAART
in improving outcome in HIVAN [16, 23–27]. In 1998,
Wali et al [23] reported a 37-year-old HIV-1–positive
African American man with HIVAN requiring hemodial-
ysis. A few months after the beginning of HAART, dialy-
sis was stopped, creatinine and proteinuria improved, and
histologic lesions recovered. A similar benefit of HAART
is reported by Kirchner [27] in two African American
patients with suspected HIVAN and in one patient with
biopsy-proven HIVAN who exhibited marked improve-
ment in renal function after treatment with two nucleo-
side RTIs and one antiprotease. In a retrospective cohort
study, Szczech et al [16] reviewed 19 patients with HIVAN
or other HIV-1–related renal diseases, leading to ESRD
in seven. Treatment with protease inhibitors (and pred-
nisone) was associated with a slower decline in renal func-
tion. Cosgrove, Abu-Alfa, and Perazella [26] reported
another retrospective series of 23 patients with HIV-1–
related nephropathies, including patients with HIVAN.
Thirteen patients, counting those with HIVAN, were
treated with HAART and none doubled their serum crea-
tinine. In the non-HAART group, all patients manifested
a doubling of serum creatinine, two patients died, and
eight required dialysis. One study [abstract; Burckle C
et al, J Am Soc Nephrol 13:381A, 2002] retrospectively
comparing two cohorts of 102 and 33 patients with biopsy-
proven-HIVAN in the pre-HAART and in the HAART
era, respectively, also argues for improvement of renal
survival by HAART. However, the lack of definitive his-
tologic diagnosis of HIVAN in some of these patients,
the absence of controls, the small number of patients
and the retrospective design of the studies did not al-
low firm conclusions to be drawn. Nonetheless, despite
the lack of definitive evidence due to the limited true
database for HAART efficacy in renal disease, we spec-
ulate that combination antiretroviral therapy constitutes
the most important therapeutic progress in preventing
ESRD in HIV-related nephropathies since the beginning
of the HIV epidemic. The idea of prospective controlled
trials evaluating HAART on HIVAN or other HIV-1–
related nephropathies is not ethically defensible, consid-
ering that the clear benefit of HAART on the survival
of HIV-infected patients does not allow the design of a
placebo-controlled group.
RENAL SIDE-EFFECTS OF ANTIRETROVIRAL
MEDICATIONS
The growing population of patients treated with
HAART and the predicted larger use of these regi-
mens in patients with previous HIV- or non-HIV–related
nephropathies requires the consideration of the poten-
tial renal side-effects of antiretroviral treatments. We
list below the anti-HIV drugs recognized or reported as
potential inducers of renal complications (summarized
in Table 1). Some renal abnormalities are only case-
reported and concern patients receiving multiple treat-
ments; therefore, their relation with an antiretroviral drug
is unclear. The renal toxicity of nonantiretroviral drugs
used in HIV patients, such as aminoglycosides, ampho-
tericin B, cidofovir, foscarnet, or pentamidine will not be
detailed here.
Protease inhibitors
Indinavir. Among protease inhibitors, indinavir is
the most frequently associated with renal or urologic
side-effects: reversible acute renal failure, chronic re-
nal failure, leukocyturia, microhematuria, mild protein-
uria, nephrolithiasis, papillary necrosis, and crystalluria
(Table 1). Symptoms may occur as early as 1 week fol-
lowing initiation of indinavir therapy [28]. They are re-
lated to the crystallization of indinavir that can occur in
all anatomic structures from the proximal tubules to the
bladder. Infrared spectrophotometry, mass spectrometry
and high-performance liquid chromatography (HPLC)
studies have confirmed that these crystals are composed
of indinavir [28, 29]. Risk factors are urine pH above 6,
high dose of indinavir, besides the usual risk factors for
nephrolithiasis (dehydration, warm environmental tem-
perature, etc.) [29–33]. Cotreatment with trimethoprim-
sulphamethoxazole or aciclovir may also constitute a
risk factor for renal or urinary indinavir-related adverse
events [34, 35]. Moreover, side-effects related to indinavir
crystallization may be synergized by renal hemodynamic
dysregulation, since indinavir reduces glomerular filtra-
tion rate (GFR) and renal blood flow (RBF) in rats [36].
The prevalence and incidence of indinavir-related uri-
nary and renal side-effects have been variably estimated.
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Table 1. Renal abnormalities reported in patients with antiretroviral agents used against human immunodeficiency virus (HIV) infection
Antiretroviral subfamily Generic name/trade name Renal abnormalities Histology References
Protease inhibitors Amprenavir/Agenerase Not reported
Indivavir/Crixivan Renal colic. flank pain, dysuria,
acute renal failure, chronic renal
failure, leukocyturia,
microhematuria, mild
proteinuria, urolithiasis,
papillary necrosis, crystalluria,
urinary tract obstruction by
radiolucent calculi, and renal
parenchymal defects
Tubulointerstitial
nephritis with
indinavir crystals
in tubules
[28, 29, 32–35,
37–47, 88–93]
Lopinavir (plus ritonavir)/Kaletra Not reported
Nelfinavir/Viracept Renal colic [48]
Ritonavir/Norvir Acute renal failure [49, 51–53]
Saquinavir/Invirase or Fortovase Not demonstrated
Nucleoside reverse
transcriptase inhibitors
Abacavir/Ziagen Acute renal failure Acute interstitial
nephritis
[81]
Didanosine/Videx Proximal tubular dysfunction
(Fanconi’s syndrome)
[77]
Lamivudine/Epivir or Zeffix Proximal tubular dysfunction
(Fanconi’s syndrome)?
[78]
Stavudine/Zerit Proximal tubular dysfunction
(Fanconi’s syndrome)?
[78]
Zalcitabine/Hivid Not reported
Zidovudine (azidothymidine)/
Retrovir
Not reported
Nucleotide reverse
transcriptase inhibitors
Tenofovir disoproxil
fumarate/Viread
Acute renal failure, proximal
tubular dysfunction (Fanconi’s
syndrome), nephrogenic
diabetes insipidus, nephritic
syndrome, leucocyturia of
apparent tubular origin
Proximal tubular
cells
abnormalities
[71–74]
Nonnucleoside reverse
transcriptase inhibitors
Delavirdine/Rescriptor Not reported
Efavirenz/Sustiva Not reported
Nevirapine/Viramune Not reported
HIV-1 fusion inhibitor Enfuvirtide Membranoproliferative nephritis? [55]
In a prospective study of 54 indinavir-naive HIV–positive
individuals by Gagnon et al [37], the prevalence of crys-
talluria was 67% at the beginning of treatment but de-
creased to 25% after 2 weeks.
The frequency of urinary complications (renal colic,
flank pain) has been estimated between 7.4% and 20.8%
[28, 34, 35, 38–40]. Kopp et al [28] evaluated the fre-
quency of indinavir-related urinary tract abnormalities.
Nineteen of the 240 patients (8%) receiving indinavir fol-
lowed over a 26-month period developed urologic symp-
toms. Of these, seven (3%) had nephrolithiasis and the
other 12 (5%) had crystalluria associated with dysuria or
with back or flank pain (of 40 patients who were not re-
ceiving indinavir, none had similar crystals). In a study
of 1219 patients, including 644 individuals treated with
indinavir, Dieleman et al [41] estimated at 8.3 per 100
treatment-years the incidence of indinavir-related uro-
logic/nephrologic symptoms (nephrolithiasis, renal colic,
flank pain, hematuria, renal failure, or nephropathy) ver-
sus 0.8 per 100 treatment-years for other HIV protease
inhibitors. The incidence of renal colic was prospectively
estimated at 23.6% over 2 years in a cohort of 555 patients
treated with a HAART regimen, including indinavir [42].
In a prospective study over 48 weeks evaluating the as-
sociation of ritonavir/indinavir, 100/800mg twice daily in
a HAART regimen, 19 (33%) out of 57 patients discon-
tinued study medication because of nephrolithiasis [43].
The frequency of mild reversible renal failure has been
estimated from 9% to 25% [32–34, 37, 40]. A retrospec-
tive analysis of patients treated with indinavir by Sar-
cletti et al [40] identified renal failure (creatinine over
1.4 mg/dL) in 13 of 72 patients (18%). It occurred after
a mean duration of indinavir treatment of 32 weeks and
was preceded by and associated with leukocyturia, with
variable microhematuria but not urolithiasis. For the most
part, renal abnormalities were reversible within 3 months
after indinavir withdrawal. However, in three out of five
patients with incomplete reversal of creatinine elevation,
histology revealed tubulointerstitial nephritis with crys-
tals in collecting ducts, tubular atrophy, and interstitial
fibrosis. The association between leukocyturia and renal
failure has been confirmed in three prospective studies,
where leukocyturia was found in 37% to 39% and in-
creased serum creatinine in 9% to 25% of adults and
children. Leukocyturia was assumed to result from the
tubulointerstitial nephritis [32, 33, 37]. In these series, re-
nal abnormalities usually reversed within 3 months after
indinavir discontinuation.
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Urinary and renal indinavir-related side-effects are
usually reversible with indinavir withdrawal and symp-
tomatic treatment, including relief of urinary tract ob-
struction if necessary [28, 32–34, 37, 40]. However, the
main problem is to continue indinavir. One must balance
between the antiretroviral efficacy of indinavir and the re-
currence of side-effects or even definitive renal injury. In-
deed, renal scarring after renal indinavir-related adverse
effects was initially suggested by the report by Tashima,
Horowitz, and Rosen [44] showing renal interstitial fibro-
sis and tubular atrophy in the renal biopsy specimen of
a woman with indinavir-related acute renal failure. Sev-
eral subsequent studies confirmed the possibility of per-
manent mild renal function decrease following indinavir
nephropathy [40, 45–47]. Whatever the nature of renal or
urinary complications, they are responsible for indinavir
discontinuation in up to 33% of patients [43]. In case of
continuation, close monitoring and preventive measures
are required to avoid relapses of the renal abnormalities:
enhancement of urine flow through increased fluid intake,
indinavir dosage adjustment, regular urine examination,
creatinine monitoring, etc.
Nelfinavir. Urinary side-effects are very rare with nel-
finavir. Only the case of one patient who experienced re-
nal colic related to a stone composed almost exclusively
of nelfinavir has been reported [48].
Ritonavir. Acute renal failure has been related to ri-
tonavir [49–53]. Increase in serum creatinine can occur
as soon as 3 days after the introduction of ritonavir and
may require dialysis. Renal failure is usually reversible
with discontinuation of the drug. Bochet et al [53] re-
ported renal failure in 12 out 87 (13.8%) patients re-
ceiving ritonavir without saquinavir. Median increase in
serum creatinine was 66% (51% to 242%). However in
this uncontrolled study, renal manifestations were not ex-
clusively attributable to ritonavir and no renal histology
was performed.
Saquinavir. Observations of renal calculi in patients
treated with saquinavir are exceptional [54], and no renal
toxicity has been attributed to saquinavir in controlled
trials.
HIV-1 fusion inhibitor
Enfuvirtide (or T20) is a new member of the anti-HIV
arsenal. It is a 36 amino acid peptide binding to the en-
velope glycoprotein 41 of HIV-1 thus inhibiting the fu-
sion of the virus and the membrane of the CD4-positive
cells. In the safety analysis of the TORO 1 and TORO
2 trials, including 663 patients treated with enfuvirtide
to evaluate its addition to a background antiviral treat-
ment, one patient with previous history of proteinuria
and hematuria exhibited a hypersensitivity reaction with
a membranoproliferative nephritis [55]. Further trials are
necessary to clearly evaluate the renal toxicity of this
drug.
Nucleotide RTIs
Adefovir, a prodrug of 9-(2-phosphonylmethoxyethyl)
adenine analogue of adenosine monophosphate (AMP),
was the first drug of a new class of nucleotide analog in-
hibitors of reverse transcriptase (RT) that now includes
two other drugs, cidofovir and tenofovir. They differ from
nucleoside RTIs in having an acyclic monophosphate
component attached to the base.
They are eliminated as unchanged drug in urine by
active secretion into the proximal tubular fluid through
proximal tubular cells [56]. Adefovir and cidofovir secre-
tion is presumably dependent on a key component of the
secretory pathway of organic anions, the renal organic an-
ion transporter 1 (OAT1), a basolateral kidney exchanger
allowing the uptake of organic anions [57].
Adefovir/cidofovir/tenofovir-related nephrotoxicity is
now well-established and is related to tubular proximal
cell toxicity responsible for Fanconi’s syndrome and renal
failure in these patients (Table 1).
Adefovir and cidofovir accumulate in proximal tubular
cells and their in vitro cytotoxicity is proportional to cellu-
lar OAT1 expression [57]. Moreover, in vitro inhibition of
OAT1 by probenecid or nonsteroidal anti-inflammatory
drugs (NSAIDs) reduces adefovir/cidofovir intracellu-
lar accumulation and cytotoxicity, strongly suggesting a
direct cytotoxic effect of adefovir/cidofovir intracellu-
lar accumulation [58]. However, the beneficial effects of
long-term coadministration of NSAIDs or probenecid
that may protect the nephrons by inhibiting proximal
tubular cell uptake of adefovir/cidofovir has not been
clearly demonstrated. In addition, it would be probably
diminished by the nephrotoxicity these drugs themselves
possess.
Adefovir is currently not approved by the federal Food
and Drug Administration (FDA) in the United States
and drug agencies from other countries for treatment
of HIV infection, due to concerns regarding serious ad-
verse effects. However, the description of adefovir re-
nal side-effects is highly instructive in the understanding
of nephrotoxicity of nucleotide RTIs. Hence, we will re-
port renal side-effects of adefovir in addition to those of
tenofovir, the sole nucleotide RTI used in HIV infection
treatment. Cidofovir is mainly used for cytomegalovirus
(CMV) infection treatment but it has a dose-dependent
renal toxicity (renal tubular toxicity responsible for Fan-
coni’s syndrome and mild to severe renal failure) that
could contribute to the renal morbidity of HIV-infected
patients [59–63].
Adefovir. In a randomized controlled trial [64],
120 mg/day adefovir nephrotoxicity occurred in up to
61% of patients after 72 weeks. Renal failure did not re-
solve within 24 weeks after adefovir discontinuation in
12% of these patients. Reducing daily dosage of adefovir
to 60 mg/day did not significantly reduce the occurrence
of renal side-effects and did not improve the reversibility
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of adefovir nephrotoxicity [65]. Similar conclusions fol-
lowed the ADHOC trial [66] and were reported by other
studies [67]. Nonetheless, two recent controlled trials suc-
cessfully evaluating adefovir for the treatment of hep-
atitis B have confirmed that the nephrotoxicity of ade-
fovir is dose-dependent, less frequent with lower dosages
(30 mg/day), and is reversible with dose reduction or in-
terruption of the treatment [68, 69].
The report by Tanji et al [70] provides some impor-
tant clues about the mechanisms of adefovir toxicity.
They reported a patient receiving 60 mg/day adefovir,
hydroxyurea, stavudine, and indinavir with acute renal
failure and proximal tubular dysfunction. These renal
abnormalities were attributed to adefovir nephrotoxicity
through an induced renal mitochondrial cytopathy. The
authors observed tubular degenerative changes of prox-
imal tubules with swollen and dysmorphic mitochondria
on histologic and ultrastructural examination. In tubu-
lar cells, respiratory chain components encoded by mi-
tochondrial DNA (cytochrome oxidase subunit I) were
selectively deficient in renal tubular cells and mitochon-
drial DNA was quantitatively reduced.
Tenofovir. Tenofovir disoproxil fumarate is the most
recent nucleotide reverse transcriptase inhibitor. As with
adefovir, renal toxicity of tenofovir has been reported.
The tenofovir-related renal abnormalities appear to be
basically similar to those observed with adefovir suggest-
ing a similar physiopathology. They consist of acute renal
failure with proximal tubular dysfunction [71–74]. Nev-
ertheless, some differences from adefovir-related lesions
are noted. In the case reported by Verhelst et al [71], renal
abnormalities, that were reversible with tenofovir with-
drawal, included a nephrogenic diabetes insipidus attest-
ing to collecting duct injury even though renal histology
demonstrated mainly proximal tubular cell abnormali-
ties. Creput et al [73] observed a patient who abruptly
developed an acute nephritic syndrome with acute re-
nal failure, Fanconi’s syndrome, and leukocyturia of ap-
parently tubular origin. Renal biopsy revealed proximal
tubular necrosis and proximal tubular cells with thin and
vacuolated cytoplasm and nuclear abnormalities suggest-
ing viral inclusions. There was mild peritubular inflamma-
tion but, surprisingly no glomerular nor vascular changes.
Two months after tenofovir discontinuation, creatinine
had not returned to its baseline level.
However, renal toxicity of tenofovir is much less fre-
quent than that observed with adefovir. In the phase I/II
trial, 49 patients were randomly assigned to receive daily
75 mg, 150 mg, 300 mg, or 600 mg tenofovir or placebo.
As of 28 days no renal abnormalities could be attributed
to tenofovir [75]. In a phase II randomized double-blind
placebo-controlled multicenter trial, 181 patients were
assigned to add 75 mg, 150 mg, or 300 mg tenofovir or
placebo to their background therapy. Safety assessments
included the effects of tenofovir on renal parameters. Af-
ter 48 weeks no renal abnormalities were observed, par-
ticularly no significant creatinine elevation as well as no
differences in changes in phosphorus levels, nor in the
incidence of proteinuria between adefovir and placebo
groups [76].
Nucleoside RTIs
Nucleoside RTIs renal toxicity is less frequent than that
of nucleotide RTIs. Two types of renal injuries have been
observed. First, nucleoside RTIs renal toxicity may in-
volve the proximal tubule similarly to nucleotide RTIs.
One case implicated didanosine [77] and one case im-
plicated lamivudine and/or stavudine [78]. Second, acute
renal failure may occur in patients with lactic acidosis
secondary to nucleoside RTI-related acquired mitochon-
drial cytopathy [70, 79, 80]. However, it is unclear whether
renal failure corresponds to an indirect mechanism ob-
served in patients with multiorgan failure requiring in-
tensive care, or is the result of a mitochondrial cytopathy
directly affecting the kidney (see below). In addition, one
publication reports a renal biopsy-documented acute im-
munoallergic interstitial nephritis related to abacavir in a
patient experiencing acute renal failure. Renal function
had improved by 2 weeks after abacavir withdrawal and
initiation of a course of corticosteroids [81].
MECHANISMS OF RTIs TUBULAR TOXICITY:
THE MITOCHONDRIAL CYTOPATHY
HYPOTHESIS
RTIs are nucleoside or nucleotide analogs that impede
HIV replication through HIV reverse transcriptase inhi-
bition. Although the selectivity of RTIs for HIV reverse
transcriptase is important, they can also inhibit DNA
polymerase from the host cell and may affect nuclear
or mitochondrial DNA. DNA polymerase c implicated
in the mitochondrial DNA (mtDNA) replication is tar-
geted by RTIs with subsequent mtDNA deletions and
secondary deficits in mtDNA-encoded enzymes of the
mitochondrial respiratory chain. Oxydative phosphory-
lation is impaired in mitochondria with deficits in en-
ergy production (ATP), intracellular lipid accumulation
upstream of the Krebs cycle and oxidative phosphory-
lation, and with production of lactate from anaerobic
respiration. At the clinical level, the mitochondrial de-
ficiency is responsible for adverse effects such as life-
threatening lactic acidosis, myopathy, cardiomyopathy,
peripheral neuropathy, pancreatitis, hepatic steatosis, and
possibly fat redistribution syndrome grouped under the
entity of RTI-induced mitochondrial cytopathy [80, 82,
83].
Therefore, it is tempting to speculate that the tubu-
lar toxicity of nucleoside or nucleotide RTI is related
to, or augmented by, renal localization of an acquired
antiretroviral-related mitochondrial cytopathy. Several
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features of RTI renal toxicity argue in favor of such an
hypothesis.
First, among recognized adverse-effects of RTIs, mito-
chondrial toxicity as well as renal toxicity are induced by
all the members of the RTI family [1, 80]. To a greater or
lesser degree, all are responsible for proximal tubular cell
toxicity that clinically manifests as proximal tubular dys-
function (Table 1). Therefore, it is tempting to make a link
between the tubular cell toxicity and the mitochondrial
toxicity of RTI.
Second, HAART-treated patients often present with
renal failure clinically and histologically related to tubu-
lointerstitial nephropathy and associated with extrarenal
manifestations attributable to mitochondrial cytopathy
(personal observations).
Third, intracellular droplets, likely lipid, are present
in proximal tubular cells of patients with renal toxicity
of tenofovir or adefovir [71, 73]. It is well established
that intracytoplasmic lipid droplets are a characteristic
of unused fatty acids in cells with defective mitochondria
[80].
Finally, the mitochondrial cytopathy hypothesis was in-
voked to explain adefovir and/or stavudine nephrotoxi-
city by Tanji et al [70] (Table 1) who reported in 2001
a patient with degenerative changes in proximal tubules
and renal tubular cells with dysmorphic mitochondria,
deficiency of the mtDNA-encoded respiratory chain and
mitochondrial DNA depletion.
The demonstration of such a mechanism has poten-
tial clinical implications in preventing renal toxicity of
RTIs. Moreover, it could help physicians to track down
mitochondrial cytopathy at an early stage with only re-
nal expression, and thus prevent extrarenal morbidity or
mortality through lactic acidosis. In this context, mea-
suring the renal impact of RTI-induced mitochondrial
cytopathy is necessary. RTIs being a cornerstone fam-
ily of drugs essential to the treatment of HIV-infected
patients, the decision to withdraw them in patients with
nephropathies cannot be based simply on conjecture.
Conversely, they cannot be continued in the face of
kidney- and life-threatening situations, thereby putting
the clinician on the horns of a true dilemma.
Prospective studies detecting mitochondrial cytopathy
in HAART-treated patients with renal abnormalities by
measuring pre- and postprandial lactate/pyruvate ratios,
and by evaluating mtDNA heteroplasmy and functional
deficit of mtDNA-encoded respiratory chain enzymes on
renal biopsies should help to assess this issue.
IS RTI-RELATED TUBULAR TOXICITY
SYNERGISTIC WITH HIV TUBULAR
REPLICATION?
The tubule is the segment predominantly targeted
by the renal toxicity of anti-HIV drugs. Consequently,
one wonders if this tubular sensitivity is worsened by
HIV-1 replication in tubular cells [12]. No studies have
compared the in vitro cytotoxicity of RTIs between
HIV-infected and control tubular cells. Moreover, the
comparison of the RTI-related renal tubular toxicity in-
cidence between clinical trials evaluating RTI in HIV-
infected patients and clinical trials evaluating RTI in non-
HIV–infected patients (patients with hepatitis B) is not
helpful since doses of cidofovir are different. Thus, there
is at present no scientific argument that favors a syner-
gistic role in the renal tubule of drug toxicity and HIV-1
replication.
The likely beneficial effect of HAART on progression
of renal failure in HIVAN strongly suggests that the ben-
efits of HAART outweigh these theoretical risks. How-
ever, we advocate particularly close monitoring for renal
side-effects in this situation.
LONG-TERM RENAL TOXICITY OF
ANTIRETROVIRAL TREATMENTS AND RENAL
SCARRING
Chronic renal abnormalities are frequently observed in
HIV-infected individuals. In this population of patients,
prevention of evolution toward chronic renal failure is
a crucial challenge. Two main possible pejorative roles
of antiviral treatments should be considered, their long-
term renal toxicity and their role in renal scarring after
acute adverse events.
Usually, the diagnosis of renal toxicity of antiretrovi-
ral treatments is evoked when patients experience acute
renal abnormalities. However, chronic renal abnormal-
ities are frequent in HAART-treated patients and the
renal toxicity of antiviral treatments may be underap-
preciated in the pathogenesis of their nephropathies.
Therefore, from a theoretical point of view, the insidious
long-term renal toxicity of antiretroviral treatments
should be taken in account in renal failure progression
and long-term longitudinal studies should be initiated to
answer this question.
Moreover, in the prospective studies evaluating safety
and efficacy of indinavir or other RTIs, a proportion of
patients with treatment-related acute renal failure did
not recover their baseline renal function (see “adefovir”
and “indinavir” sections above). These data underline the
possibility of permanent renal damage after acute renal
injury related to antiretroviral treatment.
THREATS IN PATIENTS WITH CHRONIC
KIDNEY DISEASES AND REQUIRING ANTI-HIV
THERAPY
When antiretroviral treatment is required in HIV-
infected patients with previous nephropathy, related or
unrelated to HIV infection, two nonexclusive clinical
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Table 2. Principles of the pharmacokinetic modifications according to the glomerular filtration rate (GFR) and the necessary dose adjustment for
anti-human immunodeficiency virus (HIV) medication
Antiretroviral subfamily Generic name/trade name Dose adaptation
Protease inhibitors Amprenavir/Agenerase No adaptation, contraindication of oral suspension in case
of GFR < 80 mL/min because of propyleneglycol in
excipent
Indinavir/Crixivan No data
Lopinavir (plus ritonavir)/Kaletra No adaptation
Nelfinavir/Viracept No data
Ritonavir/Norvir No data
Saquinavir/Invirase or Fortovase No adaptation
Nucleoside reverse transcriptase
inhibitors
Abacavir/Ziagen No adaptation, no data for end-stage renal failure
Didanosine/Videx Daily dosage for an adult weighing ≥ 60 kg
GFR ≥ 60 mL/min, 400 mg
GFR = 30–59 mL/min, 200 mg
GFR = 10–29 mL/min, 150 mg once daily
GFR < 10 mL/min, 100 mg once daily, after hemodialysis
Lamivudine/Epivir Daily dosage for an adult
GFR ≥ 50 mL/min, 300 mg
GFR = 30–49 mL/min, 150 mg
GFR = 15–29 mL/min, 100 mg
GFR = 5–14 mL/min, 50 mg
GFR < 5 mL/min, 25 mg
Stavudine/Zerit Daily dosage for an adult weighing ≥ 60 kg
GFR > 50 mL/min, 40 mg twice daily
GFR = 26–50 mL/min, 20 mg twice daily
GFR < 25 mL/min, 20 mg once daily, after hemodialysis
Zalcitabine/Hivid GFR = 10–40 mL/min, 0.75 mg twice daily
GFR < 10 mL/min, 0.75 mg once daily
Zidovudine (azidothymidine)/Retrovir GFR ≥ 10 mL/min, 500 to 600 mg a day
GFR < 10 mL/min, 300 to 400 mg a day
Nucleotide reverse transcriptase
inhibitors
Tenofovir disoproxil fumarate/Viread GFR ≥ 50 mL/min, 245 mg a day
GFR = 30–49 mL/min, 245 mg every 48 hours
GFR = 10–29 mL/min, 245 mg every 72 or 96 hours
Patient treated by hemodialysis, 245 mg once a week after
hemodialysis
Nonnucleoside reverse
transcriptase inhibitors
Efavirenz/Sustiva No data
Nevirapine/Viramune GFR ≥ 20 mL/min, no adaptation
GFR < 20 mL/min, no data
Hemodialysis, add 200 mg after hemodialysis
Sources are the official guidelines provided by drug manufacturers.
aspects should be discussed. For each drug, one should
measure the possible increased risk of systemic side-
effects resulting from the accumulation of drugs or of
their metabolites, and the possible risk of aggravation of
renal disease, the former possibly contributing to the lat-
ter and vice versa. Murphy, O’Hearn, and Chou [79] re-
cently published the case of a patient who illustrates these
difficulties. A 49-year-old patient with chronic renal fail-
ure (GFR estimated at 41 mL/min) was admitted to the
intensive care unit for an ultimately fatal severe lactic aci-
dosis and acute renal failure few weeks after his antiretro-
viral treatment had been changed to didanosine (without
adaptation of the dosage to his reduced GFR), tenofovir
despite renal failure, amprenavir, and ritonavir. The au-
thors comment on the increased mitochondrial toxicity
of the tenofovir/didanosine association in the context of
chronic renal failure leading to their accumulation and
worsening the renal failure.
The pharmacokinetic modifications according to the
GFR and the necessary adaptation of dose for each anti-
HIV medication are not detailed here. Their principles
are summarized in Table 2 and in two recent publications
[84, 85].
RECOMMENDATIONS TO CLINICIANS IN CASE
OF PROGRESSIVE RENAL DISEASE IN
HIV-INFECTED PATIENTS RECEIVING HAART
Despite drug adjustment, some HIV-infected patients
experience progressive renal disease. The main challenge
for the clinician is to determine the etiology of the evolv-
ing nephropathy in order to initiate specific therapeutic
intervention in addition to symptomatic measures [5].
In the setting of an HIV infection, four nonex-
clusive etiopathogenic groups of nephropathy should
be discussed: (1) HIV-related nephropathies such
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Table 3. Determining cause of renal disease in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral
therapy (HAART) (functional and obstructive renal failure being ruled out)
Renal syndrome Clinical and urinary abnormalities Etiologies Interest of renal histology
Glomerular
nephropathy
syndrome
Nephrotic range proteinuria, including
albuminuria; +/− hematuria; +/−
systemic hypertension
HIVAN; HIV-associated immune
glomerulonephritis; hepatitis B virus
related-glomerulonephritis; hepatitis C
virus related-glomerulonephritis; other
infectious glomerulonephritis;
amyloidosis
Yes (except in patent
context of HIVAN)
Vascular nephropathy
syndrome
Systemic hypertension; low-range
proteinuria; inconstant hematuria; +/−
schistocytic hemolysis and
thrombocytopenia (in TMA only)
HIV-associated TMA; TMA unrelated to
HIV; ischemic nephropathy; renal
infarction
No
Tubulointerstitial
nephropathy
syndrome
Low-range non glomerular proteinuria
(composed of low-molecular-weight
proteins such as retinol-binding protein
and/or a1 microglobulin and/or b 2
microglobulin); +/− tubular dysfunction
(Fanconi’s syndrome, tubular acidosis,
nephrogenic diabetes insipidus); no
hypertension; no hematuria
Drug nephrotoxicity; infectious
tubulointerstitial nephritis, including
mycobacterial infections
?
Abbreviations are: HIVAN, HIV-associated nephropathy; TMA, thrombotic microangiopathy. The list of diagnosis according to the renal syndrome is not exhaustive
but only indicative of the most frequent causes in the context of HIV-infected patients receiving HAART (an extensive inventory should include diseases such as
primary glomerulonephritis, not listed here because unrelated to the context).
as HIVAN, HIV-related glomerulonephritis or HIV-
associated thrombotic microangiopathy (TMA); (2) renal
diseases related to the immune deficiency such as those
induced by viral coinfection, bacterial, or parasite infec-
tion, or lymphoproliferative diseases; (3) nephropathies
related to drug toxicity, including antiretroviral therapy
side-effects; and (4) nephropathies unrelated to the HIV
infection its consequences and treatments.
Renal and extrarenal symptomatology is of particu-
lar interest in deciding between these possibilities. Typi-
cally, usual clinical characteristics and laboratory findings
will be helpful, at least to define the general type of the
nephropathy: glomerular, vascular, or tubulointerstitial.
According to the renal syndrome, the clinician will at-
tempt to distinguish between possible causes from each
of the four etiopathogenic groups of nephropathies de-
fined above. Depending on situation, renal biopsy may
be indicated. Table 3 lists the most frequent causes of
nephropathies in HIV-infected patients except for those
from etiopathogenic group 4, unrelated to the HIV infec-
tion context.
Among the glomerular nephropathies, HIV-related le-
sions (HIVAN and HIV-associated glomerulonephritis)
and glomerulonephritis complicating hepatitis B and/or
C coinfection are the most frequently observed. Prolifer-
ative glomerulonephritis may also occur as a complica-
tion of bacterial or parasitic infections. Renal histology
will be very helpful in equivocal situations and should be
performed if the potential diagnosis implies significant
changes in therapy.
In case of acute vascular nephropathy with severe hy-
pertension and TMA syndrome, HIV-related TMA or
TMA associated with opportunistic infection or lympho-
proliferative diseases are sought. Renal histology usu-
ally confirms the diagnosis with TMA lesions in small
renal arteries and/or in glomerular capillaries, but is
rarely helpful in determining the etiology. Involvement
of main renal arteries may also occur in patients receiv-
ing HAART because they are at high risk for premature
atherosclerosis [86, 87]. Progressive ischemic nephropa-
thy responsible for chronic or subacute renal failure with
vascular nephropathy syndrome and renal infarction are
the most frequent complications of renal atherosclerosis
in HAART-treated patients [10] (personal observations).
In patients with acute tubulointerstitial syndrome,
usual causes of acute tubular necrosis are easily rec-
ognized. However, in HIV patients, tubulointerstitial
nephropathies are usually more insidious, with tubular
dysfunction such as Fanconi’s syndrome, nephrogenic di-
abetes insipidus, or tubular acidosis, usually preceding the
increase in creatinine level. Particularly in this situation,
two diagnoses should be considered, infectious tubuloin-
terstitial nephritis due to mycobacteria or other organ-
isms or, more frequently, drug nephrotoxicity since the
tubules are predominantly targeted by toxicity of anti-
HIV drugs (see above and Table 1). Extrarenal clinical
manifestations and renal histology may facilitate the di-
agnosis of infectious interstitial nephritis. Regarding drug
toxicity, an attentive chronologic analysis comparing the
evolution of the renal disease and the introduction of
potentially nephrotoxic treatments may be helpful in in-
criminating a particular drug. However, in most cases, a
specific drug cannot be definitely blamed for the kidney
disease. Renal histology is usually of little help since tubu-
lar and interstitial lesions are nonspecific and its main
interest is to eliminate other causes of renal diseases.
Daugas et al: HAART-related nephropathies in HIV-infected patients 401
Occasionally, the effect of withdrawal of candidate drugs
on regression or stabilization of renal disease will be in-
formative. In more severe cases with life-threatening or
severe renal-threatening situations potentially related to
drug toxicity, withdrawal of all antiretroviral treatment
may be necessary. If a precise drug can be identified, with-
drawal and subsequent modification of the antiviral regi-
men is indicated, while attempting to maintain adequate
viral suppression special attention should be paid to the
prevention of HIV resistance which may result from ther-
apeutic modifications.
Therefore, given the large range of kidney diseases that
may occur in HIV patients on HAART, each case should
be analyzed and discussed independently regarding ben-
efits and risks of drug withdrawal.
CONCLUSION
HAART has dramatically improved survival in HIV-
infected patients. However, precautions should be taken
to prevent HAART-related nephrotoxicity or systemic
life-threatening side-effects whose risk may be increased
by renal failure. Many questions remain about the patho-
physiology of drug toxicity, but some simple rules can
already be applied to avoid having these patients experi-
ence new health complications.
Reprint requests to Eric Daugas, M.D., Ph.D., Nephrology Depart-
ment and INSERM U489, Tenon Hospital, AP-HP, 4 rue de la Chine,
75020 Paris, France.
E-mail: eric.daugas@tnn.ap-hop-paris.fr
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